All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q4 report for VIVEX BIOLOGICS on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for VIVEX BIOLOGICS · Biologics Company

All filings by THE MCMANUS GROUP · Everything VIVEX BIOLOGICS has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Florida

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Education on Human Cellular Tissue Products (HCTPs).

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Bills named in this filing 3

H.R. 5768
Skin Substitute Access and Payment Reform Act
S. 2561
Skin Substitute Access and Payment Reform Act of 2025
H.R. 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.